Lymphoma News

More than 80% of a cohort of adults with relapsed or refractory follicular lymphoma exhibited an overall response to subcutaneously administered epcoritamab-bysp, according to topline data from the agent’s manufacturer.

In this video, Joshua Brody, MD, discusses an update on pirtobrutinib for pretreated mantle cell lymphoma.

An international research collaboration has contributed new insights into how the gut microbiome contributes to the effectiveness of immunotherapy for cancer.

Patients diagnosed with relapsed or refractory lymphoma during pregnancy demonstrated a high rate of OS but low PFS rate, according to study results published in Blood Advances.

In his new role as president and CEO of The Leukemia & Lymphoma Society, pediatric hematologist oncologist E. Anders Kolb, MD, aims to expand his life’s work in advancing blood cancer research and therapies for patients of all ages.

In this video, Joshua Brody, MD, discusses an update of the ZUMA-7 trial, which was presented at ASCO Annual Meeting.

In this video, Joshua Brody, MD, discussed the results of the SWOG S1826 trial of nivolumab vs. brentuximab vedotin in advanced-stage classic Hodgkin lymphoma, which were presented at ASCO Annual Meeting.

CHICAGO — The performance of less frequent imaging and bone marrow biopsies than required by clinical trials in patients with follicular lymphoma did not impact PFS, according to data presented at ASCO Annual Meeting.

Obesity appeared strongly associated with clonal hematopoiesis of indeterminate potential — a blood condition linked to increased risk for blood cancer, according to study results published in The Journal of Clinical Investigation.

In this video, Matthew Matasar, MD, chief of the division of blood disorders at Rutgers Cancer Institute, discusses the future of DLBCL and non-Hodgkin lymphoma research.